| This week's sponsor is Pfizer. | |  | |
Top Stories Monday, November 28, 2016 Kymab has raised $100 million (€94 million) to fund the advance of its lead candidates into the clinic. The Series C round, which attracted new Chinese investors, brings the total raised by the early-stage British antibody specialist up to $220 million. Monday, November 28, 2016 Japanese biopharma Chugai, majority owned by Roche, has licensed out an early oncology prospect to Italy’s Menarini Group. Monday, November 28, 2016 The race to develop a more "natural" way to boost red blood cells in anemia patients has stepped up a gear, now that GlaxoSmithKline has started pivotal trials of its daprodustat candidate. Monday, November 28, 2016 Osaka-based Santen has seen some positives mixed with some negatives for its phase 3 ophthalmology program, but believes it has enough to warrant an NDA with the U.S. regulator. Monday, November 28, 2016 Edwards Lifesciences has penned a deal to buy Valtech Cardio for up to $690 million, less than the heart valve company looked set to be acquired for last year. The new agreement will see Edwards pay $340 million in stock and cash upfront and up to $350 million in milestones to acquire Valtech and its system for transcatheter repair of the mitral and tricuspid valves. Saturday, November 26, 2016 Donald Trump’s surprise presidential win has many industry executives taking a wait-and-see approach, including those in advertising. However, pharma company advertisers may not have as much to be wary about, according to industry executives interviewed by FiercePharma. | | | Cancer biotech Galera Therapeutics has seen a $15 million boost from new investor Sofinnova Ventures, bumping up its Series B to $57 million. Release Epizyme has been given an FDA fast-track tag for work on tazemetostat in patients with relapsed or refractory DLBCL with certain mutations. Statement Acadia's former CSO Dr. Roger Mills has become the new chief medical officer of Addex Therapeutics. Release | |
|
Resources Presented By: Lenovo Get the stats you need to start down the path to a more secure infrastructure, today. Presented By: Lenovo What's the first step to a better patient experience? The patient experience starts well before the exam room or even reception - it begins as soon as your patients pull into the parking structure. Presented by: DocuSign DocuSign’s eSignature solutions modernize healthcare and life science organizations by eliminating paper and antiquated signature processes while meeting compliance requirements and reducing costs and errors. Presented by: DocuSign The patients who rely on your scientific leadership are expecting more. Presented by: DocuSign The U.S. Department of Justice has collected upwards of $17 billion in settlements from the healthcare industry since 2009, including more than $2 billion from a single life sciences company. Sponsored By: Salesforce Life sciences companies, like many industries today, face new challenges across the board. Read More. Presented By: ISR Reports Make essential outsourced bioprocessing decisions by staying informed of industry outsourcing practices and contract manufacturer usage patterns with ISR’s Bioprocessing Services and Technologies Market Trends and Outsourcing Dynamics report. Presented By: ISR Reports ISR’s Biosimilars in the US Oncology Market (2nd Edition) report provides data and insights from 101 US-based, board-certified oncologists/hematologist oncologists as to their expectations, fears, and aspirations for biosimilars in oncology. Presented By: ISR Reports Pinpoint the information oncologists find most valuable and the best sales channels for delivering specific types of data/information. Presented By: ISR Reports ISR’s Bioprocessing Market Trends and Outsourcing Dynamics: 2016-2021 report provides an overview of the current market dynamics for bioprocessing as well as an outlook on what the marketplace will look like in five years. Presented By: ISR Reports ISR’s CRO Quality Benchmarking – Phase II/III Service Providers (8th Edition) report provides a Consumer Reports-style analysis of Phase II/III CRO service quality from hundreds of users who rated 44 Phase II/III CROs across 26 critical dimensions of quality. Presented by: Patheon Can you avoid a risky trial-and-error approach to find the right path for your poorly soluble molecule by utilizing a CDMO? Download this complimentary Whitepaper to learn more! Presented by: Biotech Primer This 3-part webinar series is specifically geared toward the non-science professional who needs to better understand industry terminology, science, techniques and issues. Sponsored by: Veeva Systems Gartner research on short- and long-term strategies for IDMP compliance. | 
